Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, transfusion, and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
| 294.23 | |
| 294.23 | |
| - | |
| 294.23 | |
| 294.23 | |
| 268.88-373.785 | |
| 8 760 M | |
| 5 079 K | |
| 2 605 M | |
| 13.4533 | |
| 0.93 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Longleaf Partners, managed by Southeastern Asset Management, released its “Partners Fund” second quarter 2024 investor letter. A copy of the letter can be downloaded here. The fund returned -6.31...
Bio-Rad Laboratories, Inc. BIO is scheduled to release second-quarter 2024 results on Aug 1, after the closing bell. The company posted adjusted earnings per share (EPS) of $2.29 in the last reported...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
